Company intelligence / Profile preview

BioXcel

New Haven, Connecticut, United States

Ownership: Public · BTAI
Employees: ~99
Development stage: Other

Overview

BioXcel Therapeutics has received FDA approval for IGALMI (dexmedetomidine sublingual film) for acute agitation in schizophrenia and bipolar disorder in adults. BXCL701, their oral innate immune activator, is in Phase 2 for small cell neuroendocrine prostate cancer and other advanced solid tumors. BXCL502 (sublingual dexmedetomidine for Alzheimer's-related agitation) is in development.

Therapeutic areas: OncologyNeurologyPsychiatry
Modalities: Small moleculeFilm-based drug deliveryOral drugInnate immunity activator
Industry: Biotech

Beyond the preview

Go deeper on BioXcel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioXcel.

Explore the full profile